CTLA4 and Autoimmunity: The therapeutic rationale for ipilimumab centers on its selective inhibition of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a critical immune checkpoint that downregulates T-cell activation to maintain immune homeostasis and prevent autoimmunity.